These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 22338219)

  • 1. [The mutation patterns of HBV P gene and genotyping in patients with lanivudine-resistant chronic hepatitis B].
    Tang JL; Zhou JK
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2011 Oct; 25(5):342-4. PubMed ID: 22338219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Identification of factors associated with YMDD mutation in patients with chronic hepatitis B receiving lamivudine treatment].
    Cao XX; Li J; Qiu LM; Luo YW; Chen YH; Ran Y
    Zhonghua Gan Zang Bing Za Zhi; 2009 Sep; 17(9):641-4. PubMed ID: 19785947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differences of YMDD mutational patterns, precore/core promoter mutations, serum HBV DNA levels in lamivudine-resistant hepatitis B genotypes B and C.
    Pan XP; Li LJ; Du WB; Li MW; Cao HC; Sheng JF
    J Viral Hepat; 2007 Nov; 14(11):767-74. PubMed ID: 17927612
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinical impact of early detection of the YMDD mutant on the outcomes of long-term lamivudine therapy in patients with chronic hepatitis B.
    Paik YH; Han KH; Hong SP; Lee HW; Lee KS; Kim SO; Shin JE; Ahn SH; Chon CY; Moon YM
    Antivir Ther; 2006; 11(4):447-55. PubMed ID: 16856618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of HIV co-infection on mutation patterns of HBV in patients with lamivudine-resistant chronic hepatitis B.
    Iacomi F; Vincenti D; Vairo F; Solmone M; Mariano A; Piselli P; Puro V; Capobianchi MR; Antonucci G
    J Med Virol; 2009 Jul; 81(7):1151-6. PubMed ID: 19475624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutational patterns of hepatitis B virus genome and clinical outcomes after emergence of drug-resistant variants during lamivudine therapy: analyses of the polymerase gene and full-length sequences.
    Enomoto M; Tamori A; Kohmoto MT; Morikawa H; Habu D; Sakaguchi H; Takeda T; Seki S; Kawada N; Shiomi S; Nishiguchi S
    J Med Virol; 2007 Nov; 79(11):1664-70. PubMed ID: 17854034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Genotype distribution of chronic hepatitis B and hepatitis C patients and investigation of the resistance patterns in hepatitis B cases].
    Kalayci R; Altindiş M; Gülamber G; Demirtürk N; Akcan Y; Demirdal T
    Mikrobiyol Bul; 2010 Apr; 44(2):237-43. PubMed ID: 20549958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis B virus genotypes B and C do not affect the antiviral response to lamivudine.
    Yuen MF; Wong DK; Sablon E; Yuan HJ; Sum SM; Hui CK; Chan AO; Wang BC; Lai CL
    Antivir Ther; 2003 Dec; 8(6):531-4. PubMed ID: 14760886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Polymerase region mutations and hepatitis B virus genotypes in chronic hepatitis B patients with poor response to lamivudine].
    Xu LJ; Pan C; Li QG; Chen RH; Zheng L; Zhang QY; Chen HC
    Zhonghua Gan Zang Bing Za Zhi; 2010 Mar; 18(3):180-3. PubMed ID: 20380793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Mutations of HBV polymerase gene sequence in lamivudine-resistant chronic hepatitis B patients].
    Wang C; Sun J; Chen JJ; Wang ZH; Hou JL
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 May; 28(5):729-30. PubMed ID: 18504191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effects comparison of lamivudine therapy for hepatitis B virus genotypes B and C].
    Zhou JL; Wu SP
    Zhonghua Gan Zang Bing Za Zhi; 2004 Aug; 12(8):489-90. PubMed ID: 15329211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiviral drug-associated potential vaccine-escape hepatitis B virus mutants in Turkish patients with chronic hepatitis B.
    Sayan M; Akhan SC
    Int J Infect Dis; 2011 Oct; 15(10):e722-6. PubMed ID: 21784687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Detection and analysis of the new kind of G743C and G743A point mutation of HBV P gene in hepatitis B virus infected patients resistant to lamivudine].
    Pan XP; Wo JE; Chen Z; Chen F; Liang WF; Liu KZ
    Zhonghua Gan Zang Bing Za Zhi; 2003 Oct; 11(10):616-8. PubMed ID: 14572341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Efficacy changes of short-term lamivudine therapy for chronic hepatitis B with emergence of YMDD mutation].
    Deng H; Lv Y; Fu J
    Zhonghua Gan Zang Bing Za Zhi; 2004 Jun; 12(6):368-9. PubMed ID: 15225437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Types and emergence time of YMDD motif mutation in hepatitis B virus polymerase gene during lamivudine treatment].
    Liang WF; Yang DH; Shen YH; Xie YJ; Zhao NF
    Zhonghua Gan Zang Bing Za Zhi; 2003 May; 11(5):302-4. PubMed ID: 12773248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pre-existing YMDD mutants in treatment-naïve patients with chronic hepatitis B are not selected during lamivudine therapy.
    Lee SH; Kim HS; Byun IS; Jeong SW; Kim SG; Jang JY; Kim YS; Kim BS
    J Med Virol; 2012 Feb; 84(2):217-22. PubMed ID: 22170540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Natural YMDD motif mutations of HBV polymerase in the chronic hepatitis B virus infected patients].
    Shin YM; Heo J; Kim GH; Kang DH; Song GA; Cho M; Yang US; Kim CM; Park HK; Jang HJ
    Taehan Kan Hakhoe Chi; 2003 Mar; 9(1):1-9. PubMed ID: 12657823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interferon-α combined with lamivudine versus lamivudine monotherapy for the emergence of YMDD mutations in chronic hepatitis B infection: a meta-analysis of randomized controlled trials.
    Zhang YL; Zhang J; Cui LY
    Hepatogastroenterology; 2015; 62(137):133-9. PubMed ID: 25911883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Individual therapy for the patients with YMDD mutation in HBV by lamivudine].
    Liu Z
    Zhonghua Gan Zang Bing Za Zhi; 2003 Sep; 11(9):558. PubMed ID: 14552722
    [No Abstract]   [Full Text] [Related]  

  • 20. Response to long-term lamivudine treatment (up to 5 years) in patients with severe chronic hepatitis B, role of genotype and drug resistance.
    Moskovitz DN; Osiowy C; Giles E; Tomlinson G; Heathcote EJ
    J Viral Hepat; 2005 Jul; 12(4):398-404. PubMed ID: 15985011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.